SUPN 36.12 (+1.66%)
US8684591089Drug ManufacturersDrug Manufacturers - Specialty & Generic

Supernus Pharmaceuticals (SUPN) Stock Highlights

36.12 | +1.66%
2024-11-21 02:57:00
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others. The majority of the revenue is generated from the sale of Trokendi XR.

Statistics

Range Today
35.32 36.5
Volume Today 203.9K
Range 1 Year
25.53 39.37
Volume 1 Year 109.99M
Range 3 Year
21.99 42.09
Volume 3 Year 323.09M
Range 10 Year
7.97 61.25
Volume 10 Year 1.43B

Highlights

Market Capitalization 2.02B (mid)
Floating Shares 47.59M
Current Price 36.12
Price To Earnings 34.11
Price To Revenue 2.54
Price To Book 2.01
Earnings Per Share 1.07
Payout Ratio 0%

Performance

Latest +1.66%
1 Month +4.6%
3 Months +5.92%
6 Months +24.85%
1 Year +31.58%
3 Years +7.6%
5 Years +67.07%
10 Years +312.33%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.